By collaborating with isolated populations, the company has developed a genome therapy that enhances drug discovery and improves treatment of complex and inherited diseases. Their approach is based on the Newfoundland founder effect, which allows for faster and more accurate identification of drug targets. Ultimately, the company's mission is to reduce the high failure rate of drug candidates and provide faster help to those in need.